NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- anti-CLEC12A/CD3 bispecific antibody MCLA117
An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A), a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential antineoplastic activity. Upon administration, anti-CLEC12A/CD3 bispecific antibody MCLA117 binds to both CD3 on T cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells (LSCs). This results in the cross-linking of T cells with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells (HSCs). Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: anti-CLEC12A x CD3 bispecific antibody MCLA117
bispecific antibody MCLA-117
Code name: MCLA 117